Biocon Biologics
Harish V. Pai currently serves as Associate Vice President and Group Portfolio Leader at Biocon Biologics since July 2022, overseeing a diverse portfolio of biosimilar programs and ensuring alignment across cross-functional teams to achieve business objectives. Previously, Harish held significant roles in analytical sciences, leading the scientific development and approval of key biosimilars such as Trastuzumab and Insulin Glargine, while also contributing as a functional bioassay subject matter expert. Harish's career at Biocon spans multiple leadership positions, including Chief Scientific Manager and Principal Scientific Manager, beginning with a foundational role as Scientific Manager. Academic credentials include a Master's degree in Biochemistry from Karnatak University and a PhD from the National Brain Research Centre, complemented by research associate experiences at Case Western Reserve University and the University of Pittsburgh School of Medicine.
This person is not in any teams
This person is not in any offices
Biocon Biologics
8 followers
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs while improving healthcare outcomes. It has a strong research pipeline of biosimilar molecules across diabetes, oncology, immunology, and other non-communicable diseases. Six molecules from Biocon Biologics’ portfolio have been taken from lab to market in developed markets like United States, EU, Australia, Canada and Japan. With a team of ~ 4,800 people, Biocon Biologics is committed to transforming healthcare and transforming lives by enabling affordable access to millions of patients’ worldwide. Follow-us on Twitter: @BioconBiologics